The wastewater levy: pharma to pay 80% of removing micropollutants, and the generics it threatens

What changed

The recast Urban Wastewater Treatment Directive, in force since the start of 2025, requires larger sewage works to add a fourth, “quaternary”, treatment stage that removes micropollutants, in stages to 2033, 2039 and 2045. Article 9 and Annex III make the producers of two product groups pay for it: medicines for human use and cosmetics, which the Commission’s impact work identified as the main sources of the micropollutants concerned. Producers must fund at least 80% of the cost through national extended-producer-responsibility schemes, with fees set by the quantity and hazard of the substances each producer places on the market. Member States must transpose the Directive by 31 July 2027 and have the schemes running by 31 December 2028. The Commission estimates the cost at €1.4–1.8 billion a year by 2045; the industry’s estimates are several times that.

Where the challenges stand

Sixteen companies and associations sued to annul the levy. On 18 February 2026 the General Court dismissed the actions as inadmissible, without ruling on the merits, because a directive addressed to Member States is not of direct concern to individual producers; several have appealed to the Court of Justice. Poland’s action for annulment, C-193/25, is the live one: on 3 September 2026 Advocate General Kokott advised the Court to annul the pharmaceutical and cosmetics provisions for want of adequate scientific justification of the choice of those two sectors. The judgment is pending, as is an Irish reference. On the political side, Parliament adopted a resolution on 18 June 2026 calling for a non-binding stop-the-clock, and Germany, Greece and Bulgaria urged postponement at the June environment council; the Commission has not paused, saying its red line is that there be no shortages.

What it means if you are…

A generics or launch planner. The levy is proportional to volume placed on the market, and the highest-volume medicines in Europe are cheap generics with regulated prices: metformin, antibiotics, analgesics, antihypertensives. A per-tonne charge on a product whose reimbursed price is set by the state and cannot be raised is a charge that comes out of a thin margin or leads to withdrawal of the least profitable national authorisations. The generics industry’s argument is exactly that, and the Commission’s “no shortages” condition is the test it has set itself. For planning, the fees will be set nationally and will differ by country, so the exposure is per market.

A parallel trader. Fees differ by country and by who counts as the producer; a parallel importer that places a pack on a market may be the producer for that pack under some national schemes. Watch the transposing laws for the definition.

A buyer. If national price regulators allow the fee to be passed through, generic prices rise in the late 2020s; if they do not, products disappear. Either way the Union list of critical medicines under the pharmaceutical package, and the Critical Medicines Act’s security-of-supply criteria, will be the counterweight.

What to watch

The Court of Justice’s judgment in C-193/25, which could remove the pharmaceutical levy altogether; the national transposition laws due by July 2027, which will say who is the producer and how fees are set; and whether the Commission or the co-legislators adopt any delay before the 2028 deadline.